Nicole R. Hadas - May 24, 2023 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Signature
/s/ Carolyn Rucci, attorney-in-fact for Nicole R. Hadas
Stock symbol
AKBA
Transactions as of
May 24, 2023
Transactions value $
-$77,270
Form type
4
Date filed
5/25/2023, 09:01 PM
Previous filing
May 16, 2023
Next filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Award $0 +200K +51.61% $0.00 588K May 24, 2023 Direct F1
transaction AKBA Common Stock Sale -$77.3K -63.2K -10.75% $1.22 524K May 25, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Employee Stock Option (Right to buy) Award $0 +200K $0.00 200K May 24, 2023 Common Stock 200K $0.41 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As previously disclosed, in May 2022, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2014 Incentive Plan, as amended. The PSUs vest upon the closing of a significant transaction as defined in the award agreement. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the PSUs vested on May 24, 2023
F2 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of all of the PSUs.
F3 As previously disclosed, in May 2022, the Reporting Person was granted performance-based options (the "Options") pursuant to the Issuer's 2014 Incentive Plan, as amended. The Options vest upon the closing of a significant transaction as defined in the award agreements. On May 24, 2023, the Company entered into a License Agreement, which transaction qualified as a significant transaction and closed on May 24, 2023. As a result, all of the shares subject to the Option vested on May 24, 2023.